NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer
July 29 2019 - 9:00AM
InvestorsHub NewsWire
NanoStilbene™ Nutraceutical Shown to Increase Ability of
Cyclophosphamide Chemotherapy to Suppress Cancer
Recent Data Supports Investigation of Commercially Available
Product
as an Adjuvant to Chemotherapy for Cancer
OCEANSIDE, CA
-- July
29,
2019 -- InvestorsHub
NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) reported today
positive animal data demonstrating synergy at suppressing growth of
cancer cells between its commercially available NanoStilbene™
nutraceutical product[1]
together
with cyclophosphamide, a type of chemotherapy. The data
indicate that NanoStilbene™, a proprietary formulation of
pterostilbene [2],
may increase the effectiveness of drugs that kill cancer through
blocking mechanistic elements of the cell division
machinery.
"The dogma in
oncology has been that chemotherapy efficacy is usually suppressed
by agents that act as antioxidants. This is because many
types of chemotherapy kill cancer cells by induction of oxidative
stress. Interestingly, the recent data suggests a
contradictory finding, in that NanoStilbene™, which is a
proprietary formulation of the antioxidant pterostilbene actually
augments the
killing
ability of cyclophosphamide,
a type of chemotherapy" said Thomas Ichim,
Ph.D., Board Member of TSOI and coinventor on the Company's
patents.
The Company
previously reported the results of a clinical
trial suggesting the efficacy of NanoStilbene in increased activity
of immune system cells termed "Natural Killer"
cells, in advanced
solid
tumor cancer patients, as
well as enhancing the
production of
interferon-gamma, a protein associated with the
suppression of cancer
growth. The study assessed
whether the administration of NanoStilbene was
effective
at reducing inflammatory markers and augmenting immune function
in those
12
advanced cancer patients.
Numerous independent
laboratories have published in the peer-reviewed literature that
pterostilbene decreases the growth of prostate cancer
[3],
breast cancer [4],
glioma [5],
liver cancer [6],
esophageal cancer [7],
and melanoma [8].
The advantage of NanoStilbene™ as compared to pterostilbene
capsules,
which are widely available, is that the proprietary nanoformulation
allows substantially higher concentrations of
pterostilbene
to reach the cancer cells.
"Last week we
reported data that NanoStilbene™ synergizes with immunotherapeutic
based drugs. The fact that we are seeing synergy with drugs
that kill cancer through completely different mechanisms suggests
that our approach is targeting multiple pathways in cancer and that
at least conceptually, tumor resistance to pterostilbene based
products should be rarer than for other drugs" said Timothy Dixon,
President, and CEO of the Company. "We plan to expand these studies
to see whether NanoStilbene™ synergizes with other types of
chemotherapies."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1]
http://www.youcanordernow.com/NanoStilbene™-PKE-60ml-wgraduated-1ml-glass-eyedropper_p_23.html
[2]
https://mynanostilbene.com/?page_id=159
[3] Dhar
et al. Oncotarget.
2015 Sep 29;6(29):27214-26.
[4]
Wakimoto
et al.
Differential Anticancer Activity of Pterostilbene Against Three
Subtypes of Human Breast Cancer Cells. Anticancer Res. 2017
Nov;37(11):6153-6159.
[5] Huynh
et al. Pterostilbene suppressed irradiation-resistant glioma stem
cells by modulating GRP78/miR-205 axis. J Nutr
Biochem.
2015 May;26(5):466-75.
[6] Qian
et al. Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN
acetylation in hepatocellular carcinoma. Biomed Pharmacother.
2018 May;101:852-859.
[7] Feng
et al. Pterostilbene Inhibits the Growth of Human Esophageal Cancer
Cells by Regulating Endoplasmic Reticulum Stress. Cell
Physiol
Biochem.
2016;38(3):1226-44.
[8]
Benlloch
et al.
Pterostilbene Decreases the Antioxidant Defenses of Aggressive
Cancer Cells In Vivo: A Physiological Glucocorticoids- and
Nrf2-Dependent Mechanism. Antioxid
Redox
Signal. 2016 Jun 10;24(17):974-90.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024